Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 7Phase 1/2 2

Status

Completed 39Terminated 15Withdrawn 7Active not recruiting 7Recruiting 5Unknown 3Suspended 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 7

Sponsor

Cancer Type

Dermatologic 4Tumor-Agnostic 2Thoracic 1

Conditions

Melanoma 4Neoplasms 2Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × trametinib × Clear all
NCT02300935 2019-05-30

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

SCRI Development Innovations, LLC

Phase 1 Withdrawn
Dermatologic

Melanoma, Neoplasm Metastasis

NCT02447939 2018-09-14

Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma

GlaxoSmithKline

Phase 1 Withdrawn
Dermatologic

Melanoma

NCT02939846 2018-09-14

Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours

GlaxoSmithKline

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT02915666 2018-05-15

A Clinical Trial of Patients With Melanoma

University of Texas Southwestern Medical Center

Phase 1 Withdrawn
Dermatologic

Melanoma

NCT02292732 2016-01-26

A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors

GlaxoSmithKline

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT02357732 2015-12-11

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib

University of Pittsburgh

Phase 1 Withdrawn
Dermatologic

Melanoma

NCT01938456 2014-07-28

Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer

GlaxoSmithKline

Phase 1 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡